Living with SFT: Surveillance and Survivorship
At a Glance
SFT requires lifelong surveillance because the tumor can recur 10 to 20 years after initial treatment. Patients follow a risk-adapted scan schedule, typically starting with frequent checks and moving to annual or biennial monitoring indefinitely to detect local recurrence or distant metastasis early.
Completing treatment for a Solitary Fibrous Tumor (SFT) is a major milestone, but it also marks the beginning of a lifelong journey of monitoring. Because SFT is known for its unpredictable behavior, “survivorship” in this context means staying vigilant even when you feel perfectly healthy [1][2].
The Reality of Late Recurrence
One of the most unique aspects of SFT is the risk of late recurrence [3]. While many cancers are considered “cured” if they don’t return within five years, SFT can reappear 10, 15, or even 20 years after the original tumor was removed [3][4].
- Local Recurrence: The tumor may grow back in the same spot where it first appeared [5].
- Distant Metastasis: SFT can spread to distant parts of the body, such as the lungs, liver, or bones [3]. For brain and spine tumors, these distant spreads have been documented as late as 9 to 13 years after diagnosis [3].
Because of this long-term risk, doctors often prefer the term No Evidence of Disease (NED) over “cured” [1]. NED means that current scans show no signs of the tumor, but it acknowledges that lifelong monitoring is necessary to catch any potential changes early [6][7].
Your Surveillance Schedule
While there is no single “one-size-fits-all” schedule, your follow-up plan will be tailored to your specific risk category (low, intermediate, or high) and the location of your tumor [8][9].
A typical surveillance plan might include:
- The First 2 Years: Frequent scans (every 3 to 6 months) using MRI or CT to monitor for early recurrence [10][11].
- Years 3 to 5: Scans may move to every 6 to 12 months if everything remains stable [12].
- Year 10 and Beyond: Unlike many other conditions, monitoring for SFT should continue indefinitely. Even after a decade of “clean” scans, annual or biennial check-ups are often recommended [3][4].
Managing ‘Scanxiety’
The stress of waiting for follow-up scans and results is so common it has its own name: Scanxiety [13][14]. This anxiety often peaks in the days leading up to the scan and during the waiting period for results [15].
To manage scanxiety, consider these evidence-based strategies:
- Minimize the Wait: Ask your doctor how quickly results will be available. Knowing you’ll hear back by a specific time can reduce the “limbo” period [16][17].
- Focus on the Present: Techniques that focus on the “here and now,” rather than worrying about future outcomes, have been shown to help reduce anticipatory distress [18][19].
- Seek Support: Having a friend or family member accompany you to appointments, or connecting with other SFT survivors, can provide vital emotional buffering [20].
- Information as Power: Understanding your specific risk and why the scans are necessary can help you feel more in control of your health journey [17].
Common questions in this guide
Why do I need scans 10 years after SFT treatment?
What is the difference between 'No Evidence of Disease' (NED) and being 'cured'?
How often will I need follow-up scans?
What is scanxiety and how can I manage it?
Where does SFT typically recur?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my tumor's risk score or WHO grade, what is my specific imaging schedule for the next 2, 5, and 10 years?
- 2.Since late recurrence is a known risk for SFT, how will our surveillance plan change after I hit the 5-year and 10-year milestones?
- 3.Which imaging modality (MRI, CT, or PET/CT) is best for monitoring my specific tumor location and checking for distant spread?
- 4.Can you explain why we use the term 'No Evidence of Disease' (NED) instead of 'cured' for my situation?
- 5.How quickly can I expect to receive my scan results to help minimize my anxiety during the waiting period?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (20)
- 1
Acute urinary retention due to solitary fibrous tumor of the abdominal wall.
Fernández-Sanmillán D, De Melo Santos DM, Fernandez EL, Hernandez JRH
Turkish journal of urology 2019; (45(6)):471-473 doi:10.5152/tud.2018.23255.
PMID: 31603423 - 2
Solitary Fibrous Tumor of the Right Elbow: A Case Report.
Mach M, Ostrowski T, Maciejewski K, et al.
Cureus 2025; (17(7)):e88175 doi:10.7759/cureus.88175.
PMID: 40687408 - 3
Central nervous system solitary fibrous tumors: Case series in accordance with the WHO 2021 reclassification. Framework for patient surveillance.
Matthijs V, Beckers R, Broecke CV, et al.
Acta neurochirurgica 2024; (166(1)):414 doi:10.1007/s00701-024-06304-7.
PMID: 39417883 - 4
Liver Metastasis From Intracranial Hemangiopericytoma 8 Years After Initial Resection: Case Report.
Hendrickson Rahmlow T, Kolagatla S, Mattingly K, et al.
Journal of investigative medicine high impact case reports 2022; (10()):23247096221132244 doi:10.1177/23247096221132244.
PMID: 36281561 - 5
Solitary Fibrous Tumors Arising from Bilateral Ovaries: A Case Report and Review of the Literature.
Tian T, Ye J, Sun J
Current medical imaging 2022; (18(8)):898-901 doi:10.2174/1573405617666211209120409.
PMID: 34886778 - 6
Adrenal solitary fibrous tumor: A case report.
Yonli DS, Chakroun M, Mokadem S, et al.
Urology case reports 2019; (27()):100919 doi:10.1016/j.eucr.2019.100919.
PMID: 31687355 - 7
Malignant solitary fibrous tumor of the orbit: Spectrum of histologic features.
Ediriwickrema LS, Burnstine M, Saber MS, Rao N
American journal of ophthalmology case reports 2017; (5()):7-10 doi:10.1016/j.ajoc.2016.10.007.
PMID: 29503937 - 8
Solitary fibrous tumor of the pineal region with delayed ectopic intracranial metastasis: A case report and review of the literature.
Wang Y, Zhang J, Liu Q, et al.
Medicine 2019; (98(21)):e15737 doi:10.1097/MD.0000000000015737.
PMID: 31124953 - 9
Hybrid video-assisted thoracoscopic resection of a massive mediastinal solitary fibrous tumor: overcoming challenges: a case report.
Deeb S, Deeb N, Douden B, et al.
Journal of medical case reports 2025; (19(1)):310 doi:10.1186/s13256-025-05377-x.
PMID: 40611223 - 10
Intracranial solitary fibrous tumor mimicking meningioma: A case report.
Cheng L, Ni H, Dai Y
Medicine 2020; (99(50)):e23504 doi:10.1097/MD.0000000000023504.
PMID: 33327290 - 11
Solitary Fibrous Tumor of Adrenal Gland and Review of the Literature.
Ambardjieva M, Saidi S, Jovanovic R, et al.
Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki) 2021; (42(3)):63-69 doi:10.2478/prilozi-2021-0036.
PMID: 35032374 - 12
Clinical analysis of 47 cases of solitary fibrous tumor.
Ge W, Yu DC, Chen G, Ding YT
Oncology letters 2016; (12(4)):2475-2480 doi:10.3892/ol.2016.4967.
PMID: 27698815 - 13
Scanxiety and Fear of Recurrence in Young Adult Female Breast and Gynaecological Cancer Survivors: Investigating Shared Mechanisms.
Patel DS, Webster SN, Dowling EJ, et al.
Psycho-oncology 2024; (33(12)):e70050 doi:10.1002/pon.70050.
PMID: 39694862 - 14
Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.
Khatri R, Quinn PL, Wells-Di Gregorio S, et al.
Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.
PMID: 39343818 - 15
Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.
Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.
European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.
PMID: 38311702 - 16
Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.
Derry-Vick HM, Heathcote LC, Glesby N, et al.
Cancers 2023; (15(5)) doi:10.3390/cancers15051381.
PMID: 36900174 - 17
Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.
Shah MS, Memon JA, Malik U, et al.
Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.
PMID: 41077027 - 18
Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.
Dunsmore VJ, Neupert SD
Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.
PMID: 36964680 - 19
The relationships between symptoms and quality of life over the course of cognitive-behavioral therapy for panic disorder in Japan.
Ogawa S, Kondo M, Okazaki J, et al.
Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists 2017; (9(2)) doi:10.1111/appy.12249.
PMID: 27481539 - 20
Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.
Hussain M, Chau S, Turner M, Paterson C
Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.
PMID: 37735038
This guide to SFT survivorship and surveillance is for educational purposes only. Always follow the specific follow-up schedule recommended by your oncology team to address your individual risk factors.
Get notified when new evidence is published on Solitary Fibrous Tumor (SFT).
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.